A London-based MedTech developing vaccines against life threatening respiratory viral infections has been acquired by French firm Sanofi in a £1.2bn deal. Vicebio Ltd, which also has head offices in Australia and Belgium, has entered an exclusive, definitive agreement, which will include an upfront payment of £850m as well as development and regulatory milestones payments … Continue reading London MedTech Vicebio to be acquired by Sanofi in £1.2bn deal